Expanding the psychedelic toolkit

Katie Kingwell

DOI: https://doi.org/10.1038/d41573-024-00100-9

IF: 112.288

2024-06-11

Nature Reviews Drug Discovery

Abstract:Nature Reviews Drug Discovery, Published online: 10 June 2024; doi:10.1038/d41573-024-00100-9 Expanding the psychedelic toolkit

pharmacology & pharmacy,biotechnology & applied microbiology

What problem does this paper attempt to address?

Decision-Making around Psychedelics for Depression and Anxiety: a Model Based on Online Discussions

David T. Kryszajtys,Jacqueline L. Bender,Brian Rush,Carol J. Strike

DOI: https://doi.org/10.1007/s11469-023-01148-1

IF: 8

2023-09-27

International Journal of Mental Health and Addiction

Abstract:Little is known about how people decide to use psychedelics to self-treat depression and anxiety, though the practice is growing. We explored online community discussions of members' decisions around self-treatment with psychedelics for depression or anxiety. We used constructivist grounded theory to select and analyze 98 members' posts across 95 discussion threads (99, 552 words) and identified a four-stage decision-making model. In stage one, decision-making began after dissatisfaction with standard mental health treatment. In stage two, members considered various psychedelic self-treatment options but explained that information was limited. In stage three, they engaged in trial and error when making decisions, despite uncertainties around safety. In stage four, they continued or discontinued self-treatment. Those who continued adapted their practice to their evolving treatment needs. Firsthand and peers' experiences informed decisions. Available scientific evidence initially validated the psychedelic self-treatment but were not instructive. Many avoided healthcare and official information sources due to stigma and legal concerns. Research and knowledge translation efforts are needed to identify general concerns with self-treatment and provide user-informed decisional support to reduce harm and maximize benefit. Services supporting psychedelic self-treatment decisions can leverage our findings to create resources based on people's lived experiences.

psychiatry,substance abuse,psychology, clinical
New frontiers in the biosynthesis of psychoactive specialized metabolites

Ginny Li,Peter J Facchini

DOI: https://doi.org/10.1016/j.pbi.2024.102626

2024-09-16

Abstract:The recent relaxation of psychedelic drug regulations has prompted extensive clinical investigation into their potential use to treat diverse mental health conditions including anxiety, depression, post-traumatic stress, and substance-abuse disorders. Most clinical trials have relied on a small number of known molecules found in nature, such as psilocybin, or long-known synthetic analogs of natural metabolites, including lysergic acid diethylamide (LSD). Elucidation of biosynthetic pathways leading to several psychedelic compounds has established an opportunity to use synthetic biology as a complement to synthetic chemistry for the preparation of novel derivatives with potentially superior pharmacological properties compared with known drugs. Herein we review the metabolic biochemistry of pathways from plants, fungi and animals that yield the medicinally important hallucinogenic specialized metabolites ibogaine, mescaline, psilocybin, lysergic acid, and N,N-dimethyltryptamine (DMT). We also summarize the reconstitution of these pathways in microorganisms and comment on the integration of native and non-native enzymes to prepare novel derivatives.
Neuroplasticity and Psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models

Claudio Agnorelli,Meg Spriggs,Kate Godfrey,Gabriela Sawicka,Bettina Bohl,Hannah Douglass,Andrea Fagiolini,Hashemi Parastoo,Robin Carhart-Harris,David Nutt,David Erritzoe

2024-11-30

Abstract:Neuroplasticity, the ability of the nervous system to adapt throughout an organism's lifespan, offers potential as both a biomarker and treatment target for neuropsychiatric conditions. Psychedelics, a burgeoning category of drugs, are increasingly prominent in psychiatric research, prompting inquiries into their mechanisms of action. Distinguishing themselves from traditional medications, psychedelics demonstrate rapid and enduring therapeutic effects after a single or few administrations, believed to stem from their neuroplasticity-enhancing properties. This review examines how classic psychedelics (e.g., LSD, psilocybin, N,N-DMT) and non-classic psychedelics (e.g., ketamine, MDMA) influence neuroplasticity. Drawing from preclinical and clinical studies, we explore the molecular, structural, and functional changes triggered by these agents. Animal studies suggest psychedelics induce heightened sensitivity of the nervous system to environmental stimuli (meta-plasticity), re-opening developmental windows for long-term structural changes (hyper-plasticity), with implications for mood and behavior. Translating these findings to humans faces challenges due to limitations in current imaging techniques. Nonetheless, promising new directions for human research are emerging, including the employment of novel positron-emission tomography (PET) radioligands, non-invasive brain stimulation methods, and multimodal approaches. By elucidating the interplay between psychedelics and neuroplasticity, this review informs the development of targeted interventions for neuropsychiatric disorders and advances understanding of psychedelics' therapeutic potential.

Neurons and Cognition,Biomolecules
Psychedelics and Neural Plasticity: Therapeutic Implications

Grieco,S. F.,Castren,E.,Knudsen,G. M.,Kwan,A. C.,Olson,D. E.,Zuo,Y.,Holmes,T. C.,Xu,X.

DOI: https://doi.org/10.1523/JNEUROSCI.1121-22.2022

2022-11-10

Journal of Neuroscience

Abstract:Psychedelic drugs have reemerged as tools to treat several brain disorders. Cultural attitudes toward them are changing, and scientists are once again investigating the neural mechanisms through which these drugs impact brain function. The significance of this research direction is reflected by recent work, including work presented by these authors at the 2022 meeting of the Society for Neuroscience. As of 2022, there were hundreds of clinical trials recruiting participants for testing the therapeutic effects of psychedelics. Emerging evidence suggests that psychedelic drugs may exert some of their long-lasting therapeutic effects by inducing structural and functional neural plasticity. Herein, basic and clinical research attempting to elucidate the mechanisms of these compounds is showcased. Topics covered include psychedelic receptor binding sites, effects of psychedelics on gene expression, and on dendrites, and psychedelic effects on microcircuitry and brain-wide circuits. We describe unmet clinical needs and the current state of translation to the clinic for psychedelics, as well as other unanswered basic neuroscience questions addressable with future studies.

neurosciences
Psychedelics as a tool for a more connected and sustainable world? Considering the importance of rituals, boundaries, and commitment.

Katie Anderson,Patrick Elf,Amy Isham

DOI: https://doi.org/10.1016/j.drugpo.2024.104571

IF: 5.931

2024-09-07

International Journal of Drug Policy

Abstract:Despite the surge of interest in psychedelic research in the past decade, largely due to the promise of psychedelics for improving mental health outcomes, there has been comparatively little discussion about the social and environmental consequences of psychedelic drug use. While there is growing evidence to suggest psychedelics could foster a greater connection to the natural world and improve social relationships, such positive repercussions are far from guaranteed. In this commentary, we focus on LSD, psilocybin and especially MDMA, and outline three insights we came to see as crucial to creating beneficial outcomes: 1) the importance of setting and rituals, 2) the establishment of boundaries, and 3) understanding the long-term commitment required. These insights are grounded in the history of psychedelics, which is intimately intertwined with ritualised use, yet the process of commercialisation of these substances threatens to strip away important contextual factors. Creating boundaries around when, how and with whom psychedelics are used have been found to protect recreational users from harm and could also be instrumental in steering commercial interests to align with socio-environmental goals. Finally, far from being a 'quick fix' for social or environmental problems, the use of psychedelics requires sustained engagement to integrate the insights obtained. Whereas we remain optimistic about the transformative potential of psychedelics for social relationships and the environment, we also emphasise the need for a more cautious, considered approach if we are to harness the benefits and minimise the challenges of psychedelic drug use.

substance abuse
Human pluripotent stem cells as a translational toolkit in psychedelic research in vitro

José Alexandre Salerno,Stevens Rehen

DOI: https://doi.org/10.1016/j.isci.2024.109631

IF: 5.8

2024-03-28

iScience

Abstract:Psychedelics, recognized for their impact on perception, are resurging as promising treatments with rapid onset for mood and substance use disorders. Despite increasing evidence from clinical trials, questions persist about the cellular and molecular mechanisms and their precise correlation with treatment outcomes. Murine neurons and immortalized non-neural cell lines harboring overexpressed constructs have shed light on neuroplastic changes mediated by the serotonin 2A receptor (5-HT2AR) as the primary mechanism. However, limitations exist in capturing human- and disease-specific traits. Here, we discuss current accomplishments and prospects for incorporating human pluripotent stem cells (PSCs) to complement these models. PSCs can differentiate into various brain cell types, mirroring endogenous expression patterns and cell identities to recreate disease phenotypes. Brain organoids derived from PSCs resemble cell diversity and patterning, while region-specific organoids simulate circuit-level phenotypes. PSC-based models hold significant promise to illuminate the cellular and molecular substrates of psychedelic-induced phenotypic recovery in neuropsychiatric disorders.
Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology

Daniel F Kelly,Keith Heinzerling,Akanksha Sharma,Shanthi Gowrinathan,Karina Sergi,Regin Jay Mallari

DOI: https://doi.org/10.1227/neu.0000000000002275

IF: 5.315

2023-04-01

Neurosurgery

Abstract:After a decades-long pause, psychedelics are again being intensely investigated for treating a wide range of neuropsychiatric ailments including depression, anxiety, addiction, post-traumatic stress disorder, anorexia, and chronic pain syndromes. The classic serotonergic psychedelics psilocybin and lysergic acid diethylamide and nonclassic psychedelics 3,4-methylenedioxymethamphetamine and ketamine are increasingly appreciated as neuroplastogens given their potential to fundamentally alter mood and behavior well beyond the time window of measurable exposure. Imaging studies with psychedelics are also helping advance our understanding of neural networks and connectomics. This resurgence in psychedelic science and psychedelic-assisted therapy has potential significance for the fields of neurosurgery and neuro-oncology and their diverse and challenging patients, many of whom continue to have mental health issues and poor quality of life despite receiving state-of-the-art care. In this study, we review recent and ongoing clinical trials, the set and setting model of psychedelic-assisted therapy, potential risks and adverse events, proposed mechanisms of action, and provide a perspective on how the safe and evidence-based use of psychedelics could potentially benefit many patients, including those with brain tumors, pain syndromes, ruminative disorders, stroke, SAH, TBI, and movement disorders. By leveraging psychedelics' neuroplastic potential to rehabilitate the mind and brain, novel treatments may be possible for many of these patient populations, in some instances working synergistically with current treatments and in some using subpsychedelic doses that do not require mind-altering effects for efficacy. This review aims to encourage broader multidisciplinary collaboration across the neurosciences to explore and help realize the transdiagnostic healing potential of psychedelics.
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology

Andrea Mastinu,Margrate Anyanwu,Marinella Carone,Giulia Abate,Sara Anna Bonini,Gregorio Peron,Emanuela Tirelli,Mariachiara Pucci,Giovanni Ribaudo,Erika Oselladore,Marika Premoli,Alessandra Gianoncelli,Daniela Letizia Uberti,Maurizio Memo

DOI: https://doi.org/10.3390/ijms24021329

IF: 5.6

2023-01-10

International Journal of Molecular Sciences

Abstract:The need to identify effective therapies for the treatment of psychiatric disorders is a particularly important issue in modern societies. In addition, difficulties in finding new drugs have led pharmacologists to review and re-evaluate some past molecules, including psychedelics. For several years there has been growing interest among psychotherapists in psilocybin or lysergic acid diethylamide for the treatment of obsessive-compulsive disorder, of depression, or of post-traumatic stress disorder, although results are not always clear and definitive. In fact, the mechanisms of action of psychedelics are not yet fully understood and some molecular aspects have yet to be well defined. Thus, this review aims to summarize the ethnobotanical uses of the best-known psychedelic plants and the pharmacological mechanisms of the main active ingredients they contain. Furthermore, an up-to-date overview of structural and computational studies performed to evaluate the affinity and binding modes to biologically relevant receptors of ibogaine, mescaline, N,N-dimethyltryptamine, psilocin, and lysergic acid diethylamide is presented. Finally, the most recent clinical studies evaluating the efficacy of psychedelic molecules in some psychiatric disorders are discussed and compared with drugs already used in therapy.

biochemistry & molecular biology,chemistry, multidisciplinary
Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines

Sean J Belouin,Lynnette A Averill,Jack E Henningfield,Stephen N Xenakis,Ingrid Donato,Charles S Grob,Ann Berger,Veronica Magar,Alicia L Danforth,Brian T Anderson

DOI: https://doi.org/10.1016/j.neuropharm.2022.109214

IF: 5.273

2022-11-15

Neuropharmacology

Abstract:There is mounting evidence suggesting psychedelic and entactogen medicines (namely psilocybin and 3,4-methylenedioxymethamphetamine [MDMA]), in conjunction with proper psychosocial support, hold the potential to provide safe, rapid acting, and robust clinical improvements with durable effects. In the US, both psilocybin and MDMA have been granted Breakthrough Therapy designations by the US Food and Drug Administration and may potentially receive full FDA approval with similar regulatory considerations occurring in multiple countries. At the same time, regulatory changes are poised to increase access to legal or decriminalized psychedelic use in various non-medical settings. This review provides a brief discussion on the historical use of psychedelic medicines, the status of the empirical evidence, and numerous significant policy considerations that must be thoughtfully addressed regarding standards-of-practice, consumer protection, engagement of communities, safeguarding access for all, and developing data standards, which supports the responsible, accountable, safe, and ethical uses of these medicines in clinical, faith-based, and other contexts. We provide suggestions for how public health and harm reduction can be supported through a public-private partnership that engages a community of stakeholders from various disciplines in the co-creation and dissemination of best practices and public policies.
CCNP Innovations in Neuropsychopharmacology Award: The psychopharmacology of psychedelics: where the brain meets spirituality

Gabriella Gobbi

DOI: https://doi.org/10.1503/jpn.240037

2024-09-19

Abstract:For 3000 years, psychedelics have been used in religious contexts to enhance spiritual thinking, well-being, and a sense of community. In the last few years, a renaissance in the use of psychedelic drugs for mental disorders has occurred in Western society; consequently, a pressing scientific need to elucidate the intricate mechanisms underlying their actions has arisen. Psychedelics mainly bind to serotonin (5-HT) receptors, particularly 5-HT2A receptors, but may also bind to other receptors. Unlike conventional psychotropic drugs used in psychiatry, psychedelics introduce a distinctive complexity. They not only engage in receptor activation, but also exert influence over specific neural circuits, thereby facilitating transformative cognitive experiences and fostering what many have identified as a spiritual contemplation or mystical experience. This comprehensive review describes clinical studies that have examined the propensity of psychedelics to enhance spiritual, mystical, and transcendent cognitive states. This multifaceted nature, encompassing diverse components and paradigms, necessitates careful consideration during the investigation of psychedelic mechanisms of action to avoid oversimplification. The present review endeavours to elucidate the mechanisms underlying the actions of 2 principal psychedelic substances, psilocybin and lysergic acid diethylamide (LSD), with a focus on monoamine and glutamate receptor mechanisms; molecular aspects, such as neuroplasticity and epigenetics; as well as the impact of psychedelics on brain circuits, including the default mode network and the cortico-striato-thalamo-cortical network. Given their distinctive and intricate mechanisms of action, psychedelics necessitate a novel conceptual framework in psychiatry, offering insight into the treatment of mental health disorders and facilitating the integration of the realms of brain, mind, and spirituality.
Integrating contextual behavioral science with research on psychedelic assisted therapy: Introduction to the special section

Jason B. Luoma,Alan K. Davis,Rosalind Watts,Lance M. McCracken

DOI: https://doi.org/10.1016/j.jcbs.2020.01.004

IF: 5.138

2020-01-01

Journal of Contextual Behavioral Science

Abstract:<p>Scientific research on the therapeutic use of psychedelics has rapidly expanded over the past decade and, over the next decade, they may be approved for clinical use. Psychedelics have been used for centuries in ritual, community, and spiritual contexts and yet the potential for a scientific approach to these drugs has possibly never been greater than it is now. Modern well controlled trials show preliminary efficacy in relation to a range of different psychological problems. In this introduction we outline the aims of this special issue, present the case for integrating psychedelics and contextual behavioral science, and provide an overview of the papers in the issue.</p>

psychology, clinical
Psychedelics and Consciousness: Expanding the Horizons of Mind and Therapy

Miyuan Zhang,Yibo Wang,Tian-Ming Gao,Xiaohui Wang

DOI: https://doi.org/10.34133/research.0495

2024-10-04

Abstract:Psychedelics have long been recognized not only for their profound impact on human consciousness but also for their potential therapeutic applications. This perspective explores the multifaceted relationship between psychedelics and consciousness, emphasizing their capacity to alter sensory perceptions, disrupt self-referential thought processes, and catalyze profound spiritual and existential experiences. As research advances, psychedelics are being integrated into therapeutic settings, challenging existing psychiatric models and offering new insights into the complex nature of consciousness and mental health. This emerging paradigm marks the need for careful regulation and ethical considerations in the therapeutic use of psychedelics, promising a more holistic approach to mental health disorders.
Making Sense of Psychedelics in the CNS

Blake A Fordyce,Bryan L Roth

DOI: https://doi.org/10.1093/ijnp/pyae007

2024-01-30

Abstract:Abstract For centuries, ancient lineages have consumed psychedelic compounds from natural sources. In the modern era, scientists have since harnessed the power of computational tools, cellular assays, and behavioral metrics to study how these compounds instigate changes on molecular, cellular, circuit-wide, and system levels. Here, we provide a brief history of psychedelics and their use in science, medicine, and culture. We then outline current techniques for studying psychedelics from a pharmacological perspective. Finally, we address known gaps in the field and potential avenues of further research to broaden our collective understanding of physiological changes induced by psychedelics, the limits of their therapeutic capabilities, and how researchers can improve and inform treatments that are rapidly becoming accessible worldwide.

pharmacology & pharmacy,neurosciences,psychiatry,clinical neurology
Psychedelic Therapy: A Primer for Primary Care Clinicians—The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics

Owen S. Muir,Kenneth Shinozuka,Bryce D. Beutler,Alejandro Arenas,Kirsten Cherian,Viviana D. Evans,Chelsey Fasano,Burton J. Tabaac

DOI: https://doi.org/10.1097/mjt.0000000000001720

2024-03-23

American Journal of Therapeutics

Abstract:The reviews in this special edition have presented a primer on the state of the literature for 7 different psychedelic compounds and their plausible roles in medicine. In a common format underscoring strengths, weakness, opportunities, and threats (SWOT), this article addresses how psychedelic compounds fit into the broader health care landscape for indicated conditions. Historically, psychiatric pathologies have been treated with small-molecule compounds that have limited effect sizes and carry a variety of adverse effect profiles. Psychedelic medicines offer the opportunity to provide more potent and rapidly acting treatments. It is crucial to note that this is an emerging field of medicine, and only one of these compounds (esketamine) is currently Food and Drug Administration-approved for depression. The other compounds discussed are investigational, and this discussion is both imaginative and prospective in nature.

pharmacology & pharmacy
Next-generation psychedelics: should new agents skip the trip?

Mark Peplow

DOI: https://doi.org/10.1038/s41587-024-02285-1

IF: 46.9

2024-06-04

Nature Biotechnology

Abstract:Companies attract venture funding for redesigned psychedelic drugs and notch clinical trial milestones.

biotechnology & applied microbiology
Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action

Lindsay P Cameron,Joseph Benetatos,Vern Lewis,Emma M Bonniwell,Alaina M Jaster,Rafael Moliner,Eero Castrén,John D McCorvy,Mikael Palner,Argel Aguilar-Valles

DOI: https://doi.org/10.1523/JNEUROSCI.1384-23.2023

2023-11-08

Abstract:Serotonergic psychedelics, such as psilocybin and LSD, have garnered significant attention in recent years for their potential therapeutic effects and unique mechanisms of action. These compounds exert their primary effects through activating serotonin 5-HT2A receptors, found predominantly in cortical regions. By interacting with these receptors, serotonergic psychedelics induce alterations in perception, cognition, and emotions, leading to the characteristic psychedelic experience. One of the most crucial aspects of serotonergic psychedelics is their ability to promote neuroplasticity, the formation of new neural connections, and rewire neuronal networks. This neuroplasticity is believed to underlie their therapeutic potential for various mental health conditions, including depression, anxiety, and substance use disorders. In this mini-review, we will discuss how the 5-HT2A receptor activation is just one facet of the complex mechanisms of action of serotonergic psychedelics. They also interact with other serotonin receptor subtypes, such as 5-HT1A and 5-HT2C receptors, and with neurotrophin receptors (e.g., tropomyosin receptor kinase B). These interactions contribute to the complexity of their effects on perception, mood, and cognition. Moreover, as psychedelic research advances, there is an increasing interest in developing nonhallucinogenic derivatives of these drugs to create safer and more targeted medications for psychiatric disorders by removing the hallucinogenic properties while retaining the potential therapeutic benefits. These nonhallucinogenic derivatives would offer patients therapeutic advantages without the intense psychedelic experience, potentially reducing the risks of adverse reactions. Finally, we discuss the potential of psychedelics as substrates for post-translational modification of proteins as part of their mechanism of action.
Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy

Andreas Halman,Rachel Conyers,Claire Moore,Dhrita Khatri,Jerome Sarris,Daniel Perkins

DOI: https://doi.org/10.1002/cpt.3459

2024-09-30

Clinical Pharmacology & Therapeutics

Abstract:Psychedelics have recently re‐emerged as potential treatments for various psychiatric conditions that impose major public health costs and for which current treatment options have limited efficacy. At the same time, personalized medicine is increasingly being implemented in psychiatry to provide individualized drug dosing recommendations based on genetics. This review brings together these topics to explore the utility of pharmacogenomics (a key component of personalized medicine) in psychedelic‐assisted therapies. We summarized the literature and explored the potential implications of genetic variability on the pharmacodynamics and pharmacokinetics of psychedelic drugs including lysergic acid diethylamide (LSD), psilocybin, N,N ‐dimethyltryptamine (DMT), 5‐methoxy‐ N,N ‐dimethyltryptamine (5‐MeO‐DMT), ibogaine and 3,4‐methylenedioxymethamphetamine (MDMA). Although existing evidence is limited, particularly concerning pharmacodynamics, studies investigating pharmacokinetics indicate that genetic variants in drug‐metabolizing enzymes, such as cytochrome P450, impact the intensity of acute psychedelic effects for LSD and ibogaine, and that a dose reduction for CYP2D6 poor metabolizers may be appropriate. Furthermore, based on the preclinical evidence, it can be hypothesized that CYP2D6 metabolizer status might contribute to altered acute psychedelic experiences with 5‐MeO‐DMT and psilocybin when combined with monoamine oxidase inhibitors. In conclusion, considering early evidence that genetic factors can influence the effects of certain psychedelics, we suggest that pharmacogenomic testing should be further investigated in clinical research. This is necessary to evaluate its utility in improving the safety and therapeutic profile of psychedelic therapies and a potential future role in personalizing psychedelic‐assisted therapies, should these treatments become available.

pharmacology & pharmacy
Psychedelics as potential catalysts of scientific creativity and insight

Sam Gandy,Valérie Bonnelle,Edward Jacobs,David Luke

DOI: https://doi.org/10.1177/20503245221097649

2022-01-01

Abstract:Creativity, that is the creation of ideas or objects considered both novel and valuable, is among the most important and highly valued of human traits, and a fundamental aspect of the sciences. Dreams and hypnagogic states have been highly influential in promoting scientific creativity and insight, contributing to some important scientific breakthroughs. Phenomenologically, the latter states of consciousness share a great deal of overlap with the psychedelic state, which has also been associated with facilitating scientific creativity on occasion. The current article proposes that the dream, hypnagogic and psychedelic states share common features that make them conducive to supporting some aspects of scientific creativity and examines the putative underlying neurophenomenological and cognitive processes involved. In addition, some notable occurrences of scientific insights that have emerged from these types of altered states are reviewed and shared common features are presented, providing a ground for future research. The psychedelic state may have its own characteristic features making it amenable to creativity enhancement, such as brain hyperconnectivity, meta-cognitive awareness, access to a more dependable and sustained altered state experience, and potential for eliciting sustained shifts in trait openness. The contextual factors which may contribute to enhancement of scientific creativity and insight will be evaluated. While research in this area is limited, further work to elucidate how psychedelics may best contribute to scientific creativity enhancement is warranted.
Bio-Psycho-Spiritual Perspectives on Psychedelics: Clinical and Ethical Implications

Logan Neitzke-Spruill,Nese Devenot,Dominic Sisti,Lynnette A. Averill,Amy L. McGuire

DOI: https://doi.org/10.1353/pbm.2024.a919715

2024-01-01

Perspectives in Biology and Medicine

Abstract:ABSTRACT: Psychedelics have again become a subject of widespread interest, owing to the reinvigoration of research into their traditional uses, possible medical applications, and social implications. As evidence for psychedelics' clinical potential mounts, the field has increasingly focused on searching for mechanisms to explain the effects of psychedelics and therapeutic efficacy of psychedelic-assisted therapy (PAT). This paper reviews three general frameworks that encompass several prominent models for understanding psychedelics' effects—specifically, neurobiological, psychological, and spiritual frameworks. Following our review, the implications of each framework for ethics and professional competencies in the implementation of psychedelics as medicines are explored. We suggest that interdisciplinary education may be necessary to improve communication between researchers, develop models that effectively incorporate multiple levels of analysis, and facilitate collaboration between professionals with diverse backgrounds in the implementation of psychedelic medicines. We also address pitfalls associated with overemphasis on neuro-mechanisms, risks associated with instigating vulnerable states of consciousness, and hurdles associated with the integration of spiritual frameworks in medicine. Ultimately, as psychedelics push the boundaries of explanatory frameworks focused on one level of analysis, developing new and more useful models to reflect knowledge being produced in this field should be a central aim of psychedelic science going forward.

medicine, research & experimental,history & philosophy of science
Unifying Theories of Psychedelic Drug Effects

Link R Swanson

DOI: https://doi.org/10.3389/fphar.2018.00172

2018-03-02

Abstract:How do psychedelic drugs produce their characteristic range of acute effects in perception, emotion, cognition, and sense of self? How do these effects relate to the clinical efficacy of psychedelic-assisted therapies? Efforts to understand psychedelic phenomena date back more than a century in Western science. In this article I review theories of psychedelic drug effects and highlight key concepts which have endured over the last 125 years of psychedelic science. First, I describe the subjective phenomenology of acute psychedelic effects using the best available data. Next, I review late 19th-century and early 20th-century theories-model psychoses theory, filtration theory, and psychoanalytic theory-and highlight their shared features. I then briefly review recent findings on the neuropharmacology and neurophysiology of psychedelic drugs in humans. Finally, I describe recent theories of psychedelic drug effects which leverage 21st-century cognitive neuroscience frameworks-entropic brain theory, integrated information theory, and predictive processing-and point out key shared features that link back to earlier theories. I identify an abstract principle which cuts across many theories past and present: psychedelic drugs perturb universal brain processes that normally serve to constrain neural systems central to perception, emotion, cognition, and sense of self. I conclude that making an explicit effort to investigate the principles and mechanisms of psychedelic drug effects is a uniquely powerful way to iteratively develop and test unifying theories of brain function.

Expanding the psychedelic toolkit

Decision-Making around Psychedelics for Depression and Anxiety: a Model Based on Online Discussions

New frontiers in the biosynthesis of psychoactive specialized metabolites

Neuroplasticity and Psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models

Psychedelics and Neural Plasticity: Therapeutic Implications

Psychedelics as a tool for a more connected and sustainable world? Considering the importance of rituals, boundaries, and commitment.

Human pluripotent stem cells as a translational toolkit in psychedelic research in vitro

Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology

The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology

Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines

CCNP Innovations in Neuropsychopharmacology Award: The psychopharmacology of psychedelics: where the brain meets spirituality

Integrating contextual behavioral science with research on psychedelic assisted therapy: Introduction to the special section

Psychedelics and Consciousness: Expanding the Horizons of Mind and Therapy

Making Sense of Psychedelics in the CNS

Psychedelic Therapy: A Primer for Primary Care Clinicians—The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics

Next-generation psychedelics: should new agents skip the trip?

Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action

Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy

Psychedelics as potential catalysts of scientific creativity and insight

Bio-Psycho-Spiritual Perspectives on Psychedelics: Clinical and Ethical Implications

Unifying Theories of Psychedelic Drug Effects